BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11468185)

  • 1. Benzene metabolites antagonize etoposide-stabilized cleavable complexes of DNA topoisomerase IIalpha.
    Baker RK; Kurz EU; Pyatt DW; Irons RD; Kroll DJ
    Blood; 2001 Aug; 98(3):830-3. PubMed ID: 11468185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etoposide targets topoisomerase IIalpha and IIbeta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique.
    Willmore E; Frank AJ; Padget K; Tilby MJ; Austin CA
    Mol Pharmacol; 1998 Jul; 54(1):78-85. PubMed ID: 9658192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
    Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of topoisomerase II-mediated DNA cleavage by benzene metabolites.
    Lindsey RH; Bender RP; Osheroff N
    Chem Biol Interact; 2005 May; 153-154():197-205. PubMed ID: 15935817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catalytic inhibition of human DNA topoisomerase IIalpha by hypericin, a naphthodianthrone from St. John's wort (Hypericum perforatum).
    Peebles KA; Baker RK; Kurz EU; Schneider BJ; Kroll DJ
    Biochem Pharmacol; 2001 Oct; 62(8):1059-70. PubMed ID: 11597574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of benzene metabolites on DNA cleavage mediated by human topoisomerase II alpha: 1,4-hydroquinone is a topoisomerase II poison.
    Lindsey RH; Bender RP; Osheroff N
    Chem Res Toxicol; 2005 Apr; 18(4):761-70. PubMed ID: 15833037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
    Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
    Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.
    Stacey DW; Hitomi M; Chen G
    Mol Cell Biol; 2000 Dec; 20(24):9127-37. PubMed ID: 11094065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topoisomerase II inhibitors fail to induce chromosome-type aberrations in etoposide-resistant cells: evidence for essential contribution of the cleavable complex formation to the induction of chromosome-type aberrations.
    Suzuki H; Tarumoto Y; Ohsawa M
    Mutagenesis; 1997 Jan; 12(1):29-33. PubMed ID: 9025094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
    Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
    Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
    Oloumi A; MacPhail SH; Johnston PJ; BanĂ¡th JP; Olive PL
    Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of human DNA topoisomerase II by hydroquinone and p-benzoquinone, reactive metabolites of benzene.
    Hutt AM; Kalf GF
    Environ Health Perspect; 1996 Dec; 104 Suppl 6(Suppl 6):1265-9. PubMed ID: 9118903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
    Satterwhite DJ; White RL; Matsunami N; Neufeld KL
    Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
    Ogiso Y; Tomida A; Lei S; Omura S; Tsuruo T
    Cancer Res; 2000 May; 60(9):2429-34. PubMed ID: 10811120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.
    Errington F; Willmore E; Tilby MJ; Li L; Li G; Li W; Baguley BC; Austin CA
    Mol Pharmacol; 1999 Dec; 56(6):1309-16. PubMed ID: 10570059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of topoisomerase II in 32D.3(G) cells by hydroquinone is associated with cell death.
    Fung J; Hoffmann MJ; Kim DD; Snyder R
    J Appl Toxicol; 2004; 24(3):183-8. PubMed ID: 15211611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
    Whitacre CM; Zborowska E; Gordon NH; Mackay W; Berger NA
    Cancer Res; 1997 Apr; 57(8):1425-8. PubMed ID: 9108439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
    Chen S; Gomez SP; McCarley D; Mainwaring MG
    Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
    Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
    Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.